Pharma Reform

Without this…. pharmaceutical companies can not succeed in the evolving new healthcare market.

What if you have a breakthrough “blockbuster” new treatment with an acceptable safety profile and few alternative therapies on the market but…

…nobody seems to be buying or prescribing your new treatment or certainly not at the rate you expected.

Why isn’t the market jumping on this new development?  Shouldn’t every patient who has the disease be at least considered for the new treatment?

How many more clinical studies do you need?  How many more patients can you possibly enroll in clinical trials to make your case?  How much more commercial effort will it take to get doctors to prescribe, formularies to consider, or patients to ask for it? How much more money will you spend trying to convince people you have a valuable treatment their patients need?

The answers are not in the product profile.  Your R & D was done to perfection. The answer is not just more clinical studies with more patients. It is not how you are selling or marketing it.  Your price is just fine and not a barrier. You don’t just need more money for advertising and promotion.  You don’t have the wrong contacts in the managed markets.

So what’s missing?  This is worth taking some time to think about…. What do you think?

Answer in next blog.    Stay tuned.

mike@pharmareform.com